Onkologie. 2009:3(2):101-105

Quality of life of patients receiving oral oncological treatment

Mgr. Zuzana Spurná1, MUDr. Dagmar, Brančíková2, MUDr. Jana Katolická3
1 Oddělení klinické psychologie FN u sv. Anny a Fakulta sociálních studií MU v Brně
2 Komplexní onkologické centrum FN u sv. Anny, Brno
3 Oddělení klinické a radiační onkologie, FN u svaté Anny v Brně

The findings of numerous studies investigating oral chemotherapy in oncological patients have proved that patients prefer oral chemotherapy

to intravenous application. Advantages of oral chemotherapy mainly include patient comfort, possible continuous administration

without being limited by long-term hospitalization and related economic advantages for the health care facility, and good

combinability with radiotherapy. Another advantage of oral preparations is that they can be combined with parenteral agents in suitable

regimens. Practical disadvantages of oral treatment include a limited possibility of physician supervision over regular administration

and having patients with tablet phobia and allergies. Resorption and impaired biotransformation of the drug in the organism may also

be of concern. The major advantage of oral chemotherapy is that it provides the patients with very good quality oncological treatment

while maintaining very good quality of life in the so-called everyday lifestyle. This good quality of life during oncological treatment, in

turn, results in a smaller degree of mental stress and higher psycho-physiological balance in the organism, thus augmenting the overall

efficacy of oncological treatment.

Keywords: quality of life, oral treatment, oncological treatment, psycho-oncology.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Spurná Z, Brančíková D, Katolická J. Quality of life of patients receiving oral oncological treatment. Onkologie. 2009;3(2):101-105.
Download citation

References

  1. Liu G, Franssen E, Fitch M, et al. Patient preference for oral versus intravenous paliative chemotherapy. J Clin Oncol 1997; 15: 110-115. Go to original source... Go to PubMed...
  2. Payne SA. A study of duality of life in cancer patiens receiving palliative chemotherapy. Soc. Sci Med 1992; 35: 1505-1509. Go to original source... Go to PubMed...
  3. Borner M, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancor. Eur J Cancor 2002; 38: 349-358. Go to original source... Go to PubMed...
  4. Topham C, Moore J. Patient preference for chemotherapy Schedule used in the treatment of advanced colorectal cancor - a pilot study. Eur J Cancor Care 1997; 6: 291-294. Go to original source... Go to PubMed...
  5. Skirvin JA, Lichtman SM. Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer Drugs and Aging, vol 19, No 1, 2002: 25-42 p.
  6. Reif S, Nicolson MC, et al. Effect of grapefruit juice intake on etoposide bioavailability Eur J Clin Pharmacol 2002. Go to original source... Go to PubMed...
  7. Spurná Z, Brančíková D, Urbánek T. Quality of life and patient preference for oral chemotherapy in metastatic colorectal carcinoma (MCRC): comparison of xelox and folfox4 regiments. Annals of oncology, ESMO 2008. Go to original source...
  8. Spurná Z, Brančíková D, Urbánek T. Comparison of the life quality of oncology patients suffering from metastasis colorectal carcinoma during the Xelox or Folfox treatment. ASCO Proceedings, ASCO 2008.
  9. Glaser R, Rice J, Speicher CE, et al. Stress depresses interferon production by leucocytes concomitant with a decrease in natural killer cell activity. Behav Neurosci 1986; 100: 675-678. Go to original source... Go to PubMed...
  10. Glaser R, Rice J, Sheridan J, et al. Stress - related immune suppression: Health implications. Brain Behav Immun 1987; 1: 7-20. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.